个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

The effect of neoadjuvant imatinib therapy on outcome and survival in rectal gastrointestinal stromal tumors: A multiinstitutional study.

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Yang Wenchang[1] ; Liu Qian[2] ; Lin Guole[3] ; Zhang Bo[4] ; Cao Hui[5] ; Zhao Yan[6] ; Xia Lijian[7] ; Feng Fan[8] ; Xiong Zhiguo[9] ; Hu Junbo[10] ; Ye Yingjiang[11] ; Tao Kaixiong[1,*1] ; Zhang Peng[1,*1] ;
机构： [1]Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. [2]Department of Colorectal Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [3]Department of General Surgery, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, China. [4]Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China. [5]Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. [6]Department of Gastric Surgery, Liaoning Cancer Hospital and Institute, Cancer Hospital of China Medical University, Shenyang, China. [7]Department of General Surgery, The First Affiliated Hospital of Shandong First Medical University, Jinan, China. [8]Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, Xi'an, China. [9]Department of Gastrointestinal Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. [10]Department of Gastrointestinal Surgery, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. [11]Department of Gastrointestinal Surgery, People's Hospital, Peking University, Beijing, China.
出处：
DOI： 10.1002/jso.26628
ISSN：

关键词： Gastrointestinal stromal tumors neoadjuvant imatinib prognosis rectum

摘要：
This study aimed to characterize the efficacy of neoadjuvant imatinib in rectal gastrointestinal stromal tumors (GISTs) and the prognostic characteristics of patients after surgery.Patients with rectal GISTs who received neoadjuvant imatinib between 2000 and 2019 were selected from 11 large-scale tertiary hospitals in China. The best response to neoadjuvant imatinib was assessed. Propensity score matching (PSM) was conducted to reduce confounders. Recurrence free survival (RFS) and overall survival (OS) were estimated using Kaplan-Meier method.Of the 100 patients, 75, 18, and 7 had a partial response (PR), stable disease (SD), and progressive disease (PD), respectively. The median tumor size decreased from 5 cm before treatment to 4 cm after treatment (p < 0.001). A total of 31 patients underwent genetic testing after surgery; 23 of patients with exon 11 mutation had PR and 2 had SD. One of the patients with exon 9 mutation had PR, 2 had SD, and 1 had PD. Two patients with the wild type GIST had PD. A total of 86 patients underwent surgery of which 85 underwent complete resection; 72 underwent anal preservation and 40 underwent local excision (LE). After PSM, patients who received neoadjuvant therapy had higher rates of LE (p = 0.001) and anal preservation (p = 0.033) than those of patients without neoadjuvant therapy. The median follow-up time was 37 months. Nine patients experienced recurrence and one patient died. The 3-year RFS and OS rates were 95.0% and 100%, respectively. After PSM, we found that there was no significant difference in RFS between patients who received or did not receive neoadjuvant therapy (p = 0.623). Univariate analysis showed postneoadjuvant tumor size (p = 0.469) and mitotic count (p = 0.294) were not associated with the RFS in patients who received neoadjuvant imatinib.Neoadjuvant imatinib can shrink rectal GIST size, increasing the possibility of complete resection and anal preservation. Further studies are warranted to understand the long-term outcomes of rectal GISTs in patients receiving neoadjuvant imatinib.© 2021 Wiley Periodicals LLC.

基金：
National Natural Science Foundation of China, Grant/Award Number: 81874184
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2021]版：
大类 | 3 区 医学
小类 | 3 区 肿瘤学 3 区 外科
最新[2023]版：
大类 | 3 区 医学
小类 | 3 区 肿瘤学 3 区 外科
JCR分区：
出版当年[2021]版：
Q2 SURGERY Q4 ONCOLOGY
最新[2023]版：
Q2 SURGERY Q3 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者机构： [1]Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
共同第一作者：
通讯作者：
通讯机构： [1]Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. [*1]Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan 430022, Hubei, China.
推荐引用方式(GB/T 7714)：
Yang Wenchang,Liu Qian,Lin Guole,et al.The effect of neoadjuvant imatinib therapy on outcome and survival in rectal gastrointestinal stromal tumors: A multiinstitutional study.[J].JOURNAL OF SURGICAL ONCOLOGY.2021,124(7):1128-1135.doi:10.1002/jso.26628.
APA：
Yang Wenchang,Liu Qian,Lin Guole,Zhang Bo,Cao Hui...&Zhang Peng.(2021).The effect of neoadjuvant imatinib therapy on outcome and survival in rectal gastrointestinal stromal tumors: A multiinstitutional study..JOURNAL OF SURGICAL ONCOLOGY,124,(7)
MLA：
Yang Wenchang,et al."The effect of neoadjuvant imatinib therapy on outcome and survival in rectal gastrointestinal stromal tumors: A multiinstitutional study.".JOURNAL OF SURGICAL ONCOLOGY 124..7(2021):1128-1135

相关文献

[1]Tenascin-C expression is significantly associated with the progression and prognosis in gastric GISTs. [2]胃肠间质瘤研究进展 [3]Clinicopathologic Characteristics and Prognosis of PDGFRA-Mutant Gastrointestinal Stromal Tumors: A Large-Scale, Multi-Institutional, Observational Study in China [4]Long-term survival among patients with gastrointestinal stromal tumors diagnosed after another malignancy: a SEER population-based study. [5]Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors [6]Total laparoscopic segmental gastrectomy for gastrointestinal stromal tumors: A case report [7]An ultrasound based method for predicting the malignant potential of primary gastrointestinal stromal tumors preoperatively [8]Gastrointestinal stromal tumors regulate macrophage M2 polarization through the MIF/CXCR4 axis to immune escape [9]CT features combined with RECIST 1.1 criteria improve progression assessments of sunitinib-treated gastrointestinal stromal tumors [10]Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors.

资源点击量：46425 今日访问量：0 总访问量：3323 更新日期：2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号